Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval
FREE Breaking News Alerts from StreetInsider.com!
More News related to AMLN Notable 52-Week Highs and Lows of the Day 02/02: (AMLN) (QCOM) (CDNS) High; (ANF) (CMED) (CMRG) Low Stocks with implied volatility movement; AMLN BTU Amylin Pharmaceuticals to Webcast 2011 Year-End Financial Results Analyst Sees Increased Chance of Amylin (AMLN) Takeover Amid Bydureon Approval Unusual 11 Midday Movers 01/30: (GTXI) (ONCY) (PBY) Higher; (CTIC) (EMKR) (PMC) Lower More News related to AMLN
More News related to Analyst Comments Shares of Allegiant Travel (ALGT) Take Breather After Six-Month Climb Shares of Tractor Supply (TSCO) Fall After Q4 Report; Wall Street Firms Remain Positive Barclays Maintains an 'Overweight' on Shutterfly (SFLY); Cutting Numbers as Guidance Reflects Growing Competition Jefferies Maintains a 'Hold' on Autoliv, Inc. (ALV); Follow-Up to Q4 Results Baird Chimes In on Zynga (ZNGA) After Facebook Boost More News related to Analyst Comments January 30, 2012 2:52 PM EST Piper Jaffray's Ian Somaiya issued a note Monday morning suggesting FDA approval of Bydureon increases chances for a takeover of Amylin (Nasdaq: AMLN).
Somaiya believes Amylin could be worth $33 per share based on an average multiple; applying a historic multiple which assumes peak sales gets the value into the $37-$49 per share range.
Piper Jaffray maintains an Overweight rating and $17 price target on shares of Amylin